

## **RAW SEQUENCE LISTING**

**The Biotechnology Systems Branch of the Scientific and Technical  
Information Center (STIC) no errors detected.**

Application Serial Number: 10|550,632  
Source: JFWO  
Date Processed by STIC: 7/7/06

***ENTERED***



IFWO

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/550,632

DATE: 12/07/2006

TIME: 14:17:58

Input Set : N:\efs\12\_07\_06\10550632\_efs\seqlist.txt  
 Output Set: N:\CRF4\12072006\J550632.raw

```

4 <110> APPLICANT: Argoud-Puy, Guilaine
5      Bederr, Nassima
6      Bougueleret, Lydie
7      Cusin, Isabelle
8      Mah?, Eve
9      Niknejad, Anne
10     Reffas, Samia
13 <120> TITLE OF INVENTION: SECRETED POLYPEPTIDE SPECIES ASSOCIATED
14 WITH CARDIOVASCULAR DISORDERS
17 <130> FILE REFERENCE: 33624 US-PCT GEP5032
19 <140> CURRENT APPLICATION NUMBER: 10/550,632
C--> 20 <141> CURRENT FILING DATE: 2005-09-23
22 <150> PRIOR APPLICATION NUMBER: 60/461,558
23 <151> PRIOR FILING DATE: 2003-04-08
25 <150> PRIOR APPLICATION NUMBER: 60/461,623
26 <151> PRIOR FILING DATE: 2003-04-08
28 <150> PRIOR APPLICATION NUMBER: 60/471,479
29 <151> PRIOR FILING DATE: 2003-05-16
31 <150> PRIOR APPLICATION NUMBER: 60/474,863
32 <151> PRIOR FILING DATE: 2003-05-30
34 <150> PRIOR APPLICATION NUMBER: 60/484140
35 <151> PRIOR FILING DATE: 2003-06-30
37 <150> PRIOR APPLICATION NUMBER: PCT/EP2004/003737
38 <151> PRIOR FILING DATE: 2004-04-07
40 <160> NUMBER OF SEQ ID NOS: 147
42 <170> SOFTWARE: FastSEQ for Windows Version 4.0
44 <210> SEQ ID NO: 1
45 <211> LENGTH: 95
46 <212> TYPE: PRT
47 <213> ORGANISM: Homo sapiens
49 <220> FEATURE:
50 <221> NAME/KEY: PEPTIDE
51 <222> LOCATION: (1)...(95)
52 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2
53 (CPP-2) peptide. SEQ ID NOS:1 and 2 describe the
54 amino acid sequences of the Colipase polypeptides
55 present in plasma samples of individuals with
W--> 56 coronary artery disease (hereinafter SEQ ID NO:2
W--> 57 is designated CPP-2).
59 <400> SEQUENCE: 1
60 Ala Pro Gly Pro Arg Gly Ile Ile Ile Asn Leu Glu Asn Gly Glu Leu
61 1          5          10          15
62 Cys Met Asn Ser Ala Gln Cys Lys Ser Asn Cys Cys Gln His Ser Ser

```

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/550,632

DATE: 12/07/2006  
TIME: 14:17:58

Input Set : N:\efs\12\_07\_06\10550632\_efs\seqlist.txt  
Output Set: N:\CRF4\12072006\J550632.raw

63               20               25               30  
 64 Ala Leu Gly Leu Ala Arg Cys Thr Ser Met Ala Ser Glu Asn Ser Glu  
 65               35               40               45  
 66 Cys Ser Val Lys Thr Leu Tyr Gly Ile Tyr Tyr Lys Cys Pro Cys Glu  
 67               50               55               60  
 68 Arg Gly Leu Thr Cys Glu Gly Asp Lys Thr Ile Val Gly Ser Ile Thr  
 69 65              70              75              80  
 70 Asn Thr Asn Phe Gly Ile Cys His Asp Ala Gly Arg Ser Lys Gln  
 71               85               90               95  
 74 <210> SEQ ID NO: 2  
 75 <211> LENGTH: 90  
 76 <212> TYPE: PRT  
 77 <213> ORGANISM: Homo sapiens  
 79 <220> FEATURE:  
 80 <221> NAME/KEY: PEPTIDE  
 81 <222> LOCATION: (1)...(90)  
 82 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2  
 83               (CPP-2) peptide. SEQ ID NOs:1 and 2 describe the  
 84               amino acid sequences of the Colipase polypeptides  
 85               present in plasma samples of individuals with  
 W--> 86               coronary artery disease (hereinafter, SEQ ID NO:2  
 W--> 87               is designated CPP 2).  
 89 <400> SEQUENCE: 2  
 90 Gly Ile Ile Ile Asn Leu Glu Asn Gly Glu Leu Cys Met Asn Ser Ala  
 91 1               5               10               15  
 92 Gln Cys Lys Ser Asn Cys Cys Gln His Ser Ser Ala Leu Gly Leu Ala  
 93               20               25               30  
 94 Arg Cys Thr Ser Met Ala Ser Glu Asn Ser Glu Cys Ser Val Lys Thr  
 95               35               40               45  
 96 Leu Tyr Gly Ile Tyr Tyr Lys Cys Pro Cys Glu Arg Gly Leu Thr Cys  
 97               50               55               60  
 98 Glu Gly Asp Lys Thr Ile Val Gly Ser Ile Thr Asn Thr Asn Phe Gly  
 99 65              70              75              80  
 100 Ile Cys His Asp Ala Gly Arg Ser Lys Gln  
 101               85               90  
 104 <210> SEQ ID NO: 3  
 105 <211> LENGTH: 14  
 106 <212> TYPE: PRT  
 107 <213> ORGANISM: Homo sapiens  
 109 <220> FEATURE:  
 110 <221> NAME/KEY: PEPTIDE  
 111 <222> LOCATION: (1)...(14)  
 112 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2  
 113               (CPP-2) peptide. EQ ID NOs:3-5 are the amino acid  
 114               sequences of tryptic peptides found in MS-MS  
 115               and/or MS-MALDI mass spectrometry in plasma  
 W--> 116               samples of individuals with coronary artery  
 W--> 117               disease.  
 119 <400> SEQUENCE: 3

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/550,632

DATE: 12/07/2006

TIME: 14:17:58

Input Set : N:\efs\12\_07\_06\10550632\_efs\seqlist.txt  
 Output Set: N:\CRF4\12072006\J550632.raw

120 Ser Asn Cys Cys Gln His Ser Ser Ala Leu Gly Leu Ala Arg  
 121 1 5 10  
 124 <210> SEQ ID NO: 4  
 125 <211> LENGTH: 14  
 126 <212> TYPE: PRT  
 127 <213> ORGANISM: Homo sapiens  
 129 <220> FEATURE:  
 130 <221> NAME/KEY: PEPTIDE  
 131 <222> LOCATION: (1)...(14)  
 132 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2  
 133 (CPP-2) peptide. EQ ID NOS:3-5 are the amino acid  
 134 sequences of tryptic peptides found in MS-MS  
 135 and/or MS-MALDI mass spectrometry in plasma  
**W--> 136 samples of individuals with coronary artery**  
**W--> 137 disease.**  
 139 <400> SEQUENCE: 4  
 140 Cys Thr Ser Met Ala Ser Glu Asn Ser Glu Cys Ser Val Lys  
 141 1 5 10  
 144 <210> SEQ ID NO: 5  
 145 <211> LENGTH: 19  
 146 <212> TYPE: PRT  
 147 <213> ORGANISM: Homo sapiens  
 149 <220> FEATURE:  
 150 <221> NAME/KEY: PEPTIDE  
 151 <222> LOCATION: (1)...(19)  
 152 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2  
 153 (CPP-2) peptide. EQ ID NOS:3-5 are the amino acid  
 154 sequences of tryptic peptides found in MS-MS  
 155 and/or MS-MALDI mass spectrometry in plasma  
**W--> 156 samples of individuals with coronary artery**  
**W--> 157 disease.**  
 159 <400> SEQUENCE: 5  
 160 Thr Ile Val Gly Ser Ile Thr Asn Thr Asn Phe Gly Ile Cys His Asp  
 161 1 5 10 15  
 162 Ala Gly Arg  
 166 <210> SEQ ID NO: 6  
 167 <211> LENGTH: 161  
 168 <212> TYPE: PRT  
 169 <213> ORGANISM: Homo sapiens  
 171 <220> FEATURE:  
 172 <221> NAME/KEY: PEPTIDE  
 173 <222> LOCATION: (1)...(161)  
 174 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 9  
 175 (CPP-9) peptide. SEQ ID NO:6 describes the amino  
 176 acid sequence of eosinophil-derived neurotoxin  
 177 (EDN, hereinafter CPP-9), whereas SEQ ID NO:7 is  
**W--> 178 the polypeptide sequence of the mature protein.**  
 180 <400> SEQUENCE: 6  
 181 Met Val Pro Lys Leu Phe Thr Ser Gln Ile Cys Leu Leu Leu

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/550,632

DATE: 12/07/2006

TIME: 14:17:58

Input Set : N:\efs\12\_07\_06\10550632\_efs\seqlist.txt  
 Output Set: N:\CRF4\12072006\J550632.raw

```

182   1           5           10          15
183 Gly Leu Leu Ala Val Glu Gly Ser Leu His Val Lys Pro Pro Gln Phe
184           20          25          30
185 Thr Trp Ala Gln Trp Phe Glu Thr Gln His Ile Asn Met Thr Ser Gln
186           35          40          45
187 Gln Cys Thr Asn Ala Met Gln Val Ile Asn Asn Tyr Gln Arg Arg Cys
188           50          55          60
189 Lys Asn Gln Asn Thr Phe Leu Leu Thr Thr Phe Ala Asn Val Val Asn
190 65           70          75          80
191 Val Cys Gly Asn Pro Asn Met Thr Cys Pro Ser Asn Lys Thr Arg Lys
192           85          90          95
193 Asn Cys His His Ser Gly Ser Gln Val Pro Leu Ile His Cys Asn Leu
194           100         105         110
195 Thr Thr Pro Ser Pro Gln Asn Ile Ser Asn Cys Arg Tyr Ala Gln Thr
196           115         120         125
197 Pro Ala Asn Met Phe Tyr Ile Val Ala Cys Asp Asn Arg Asp Gln Arg
198           130         135         140
199 Arg Asp Pro Pro Gln Tyr Pro Val Val Pro Val His Leu Asp Arg Ile
200 145           150         155         160
201 Ile
205 <210> SEQ ID NO: 7
206 <211> LENGTH: 134
207 <212> TYPE: PRT
208 <213> ORGANISM: Homo sapiens
210 <220> FEATURE:
211 <221> NAME/KEY: PEPTIDE
212 <222> LOCATION: (1)...(134)
213 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 9
214 (CPP-9) peptide. SEQ ID NO:6 describes the amino
215 acid sequence of eosinophil-derived neurotoxin
216 (EDN, hereinafter CPP-9), whereas SEQ ID NO:7 is
W--> 217 the polypeptide sequence of the mature protein.
219 <400> SEQUENCE: 7
220 Lys Pro Pro Gln Phe Thr Trp Ala Gln Trp Phe Glu Thr Gln His Ile
221   1           5           10          15
222 Asn Met Thr Ser Gln Gln Cys Thr Asn Ala Met Gln Val Ile Asn Asn
223           20          25          30
224 Tyr Gln Arg Arg Cys Lys Asn Gln Asn Thr Phe Leu Leu Thr Thr Phe
225           35          40          45
226 Ala Asn Val Val Asn Val Cys Gly Asn Pro Asn Met Thr Cys Pro Ser
227           50          55          60
228 Asn Lys Thr Arg Lys Asn Cys His His Ser Gly Ser Gln Val Pro Leu
229 65           70          75          80
230 Ile His Cys Asn Leu Thr Thr Pro Ser Pro Gln Asn Ile Ser Asn Cys
231           85          90          95
232 Arg Tyr Ala Gln Thr Pro Ala Asn Met Phe Tyr Ile Val Ala Cys Asp
233           100         105         110
234 Asn Arg Asp Gln Arg Arg Asp Pro Pro Gln Tyr Pro Val Val Pro Val
235           115         120         125

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/550,632

DATE: 12/07/2006

TIME: 14:17:58

Input Set : N:\efs\12\_07\_06\10550632\_efs\seqlist.txt  
Output Set: N:\CRF4\12072006\J550632.raw

236 His Leu Asp Arg Ile Ile  
237 130  
240 <210> SEQ ID NO: 8  
241 <211> LENGTH: 17  
242 <212> TYPE: PRT  
243 <213> ORGANISM: Homo sapiens  
245 <400> SEQUENCE: 8  
246 Tyr Ala Gln Thr Pro Ala Asn Met Phe Tyr Ile Val Ala Cys Asp Asn  
247 1 5 10 15  
248 Arg  
252 <210> SEQ ID NO: 9  
253 <211> LENGTH: 15  
254 <212> TYPE: PRT  
255 <213> ORGANISM: Homo sapiens  
257 <220> FEATURE:  
258 <221> NAME/KEY: PEPTIDE  
259 <222> LOCATION: (1)...(15)  
260 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 9  
261 (CPP-9) peptide. SEQ ID NOS:8, 9, and 10 are the  
262 amino acid sequences of tryptic peptides found by  
263 MS-MS mass spectrometry in plasma samples of  
W--> 264 individuals with coronary artery disease.  
266 <400> SEQUENCE: 9  
267 Arg Asp Pro Pro Gln Tyr Pro Val Val Pro Val His Leu Asp Arg  
268 1 5 10 15  
271 <210> SEQ ID NO: 10  
272 <211> LENGTH: 14  
273 <212> TYPE: PRT  
274 <213> ORGANISM: Homo sapiens  
276 <220> FEATURE:  
277 <221> NAME/KEY: PEPTIDE  
278 <222> LOCATION: (1)...(14)  
279 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 9  
280 (CPP-9) peptide. SEQ ID NOS:8, 9, and 10 are the  
281 amino acid sequences of tryptic peptides found by  
282 MS-MS mass spectrometry in plasma samples of  
W--> 283 individuals with coronary artery disease.  
285 <400> SEQUENCE: 10  
286 Asp Pro Pro Gln Tyr Pro Val Val Pro Val His Leu Asp Arg  
287 1 5 10  
290 <210> SEQ ID NO: 11  
291 <211> LENGTH: 151  
292 <212> TYPE: PRT  
293 <213> ORGANISM: Homo sapiens  
295 <220> FEATURE:  
296 <221> NAME/KEY: PEPTIDE  
297 <222> LOCATION: (1)...(151)  
298 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 21  
299 (CPP-21) peptide. SEQ ID NO:11 describes the amino

VERIFICATION SUMMARY  
PATENT APPLICATION: US/10/550,632

DATE: 12/07/2006  
TIME: 14:17:59

Input Set : N:\efs\12\_07\_06\10550632\_efs\seqlist.txt  
Output Set: N:\CRF4\12072006\J550632.raw

L:20 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:56 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:57 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:86 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:87 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:116 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:117 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:136 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:137 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:156 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:157 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:178 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:217 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:264 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:283 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:302 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:303 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:340 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:341 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:376 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:377 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:398 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:399 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:418 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:419 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:420 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:449 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:450 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:451 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:478 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:479 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:480 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:501 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:502 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:523 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:524 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:543 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:544 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:563 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:564 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:583 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:584 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:603 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:604 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:623 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:624 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:653 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:654 M:259 W: Allowed number of lines exceeded, <223> Other Information:

**VERIFICATION SUMMARY**

PATENT APPLICATION: US/10/550,632

DATE: 12/07/2006

TIME: 14:17:59

Input Set : N:\efs\12\_07\_06\10550632\_efs\seqlist.txt  
Output Set: N:\CRF4\12072006\J550632.raw

L:681 M:259 W: Allowed number of lines exceeded, <223> Other Information:

L:702 M:259 W: Allowed number of lines exceeded, <223> Other Information:

L:721 M:259 W: Allowed number of lines exceeded, <223> Other Information: